Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that
President and Chief Executive Officer, Igor Gonda, Ph.D., will present
at the 19th Annual BIO CEO & Investor Conference 2017 on
Monday, February 13, 2017, at 1:30 p.m. ET. The event will be held at
the Waldorf-Astoria Hotel in New York, New York.
Interested parties can access a live audio webcast and slide
presentation at www.aradigm.com.
An archived presentation will be available on the Company's Web site for
Aradigm is an emerging specialty pharmaceutical company focused on the
development and commercialization of drugs for the prevention and
treatment of severe respiratory diseases. Aradigm is completing Phase 3
development of Pulmaquin® (an investigational proprietary formulation of
ciprofloxacin for inhalation) for the treatment of non-cystic fibrosis
bronchiectasis. Aradigm's inhaled ciprofloxacin formulations including
Pulmaquin are also product candidates for treatment of patients with
cystic fibrosis and non-tuberculous mycobacteria, and for the prevention
and treatment of high threat and bioterrorism infections, such as
inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled
anthrax. In addition, Aradigm has a pipeline composed of programs to
prevent diseases in tobacco smokers through smoking cessation and a
diagnostic program to detect aspirations of gastrointestinal fluid into
the respiratory tract.
More information about Aradigm can be found at www.aradigm.com.
Aradigm and the Aradigm Logo are registered trademarks of Aradigm
View source version on businesswire.com: http://www.businesswire.com/news/home/20170209005217/en/
Nancy Pecota, 510-265-8800
Source: Aradigm Corporation
News Provided by Acquire Media